# RNA splicing dysregulation and the hallmarks of cancer

Source: https://onco.cc/key-papers/paper-bradley-nat-rev-cancer/  
OnCo record `paper-bradley-nat-rev-cancer` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paper cited by one pathway page, indexed on Europe PMC as PubMed record 36627445 and published in Nature Reviews Cancer; the citing page links this DOI, which is how the record was matched.

## Summary

Dysregulated RNA splicing is a molecular feature that characterizes almost all tumour types. Cancer-associated splicing alterations arise from both recurrent mutations and altered expression of trans-acting factors governing splicing catalysis and regulation. Cancer-associated splicing dysregulation can promote tumorigenesis via diverse mechanisms, contributing to increased cell proliferation, decreased apoptosis, enhanced migration and metastatic potential, resistance to chemotherapy and evasion of immune surveillance. Recent studies have identified specific cancer-associated isoforms that play critical roles in cancer cell transformation and growth and demonstrated the therapeutic benefits of correcting or otherwise antagonizing such cancer-associated mRNA isoforms. Clinical-grade small molecules that modulate or inhibit RNA splicing have similarly been developed as promising anticancer therapeutics. Here, we review splicing alterations characteristic of cancer cell transcriptomes, dysregulated splicing's contributions to tumour initiation and progression, and existing and emerging approaches for targeting splicing for cancer therapy. Finally, we discuss the outstanding questions and challenges that must be addressed to translate these findings into the clinic.

Indexed on Europe PMC as PubMed record 36627445 (DOI 10.1038/s41568-022-00541-7). Matched by DOI alone: one pathway page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Nature Reviews Cancer
- Year: 2023
- DOI: 10.1038/s41568-022-00541-7
- Authors: Bradley RK, Anczuków O
- What it means: One pathway page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Caveats: Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.

## Sources

- Nat Rev Cancer 2023: https://doi.org/10.1038/s41568-022-00541-7
- PubMed: https://pubmed.ncbi.nlm.nih.gov/36627445/
- Europe PMC: https://europepmc.org/article/MED/36627445

## Connected records

- pathways: [RNA splicing](https://onco.cc/pathways/rna-splicing/)
- journals: [Nature Reviews Cancer](https://onco.cc/journals/nature-reviews-cancer/)

---
JSON: https://onco.cc/api/v1/entities/paper-bradley-nat-rev-cancer.json